Aiming, I haven't had a chance to dig into Peregrine yet, but I did add several names to my growing list of longer term holdings (now up to 18). The new additions are Imclone (possible buyout target), and several larger caps I've liked for a long time - Genzyme and Gilead, plus the generic company Teva (very well run company and they're buying competitor Ivax). I'm beginning to see the logic in some of Dew's picks (I think he likes Teva and Imclone).
Here's my updated list of 18 stocks for the longer haul -
Atherogenics
Biomarin
Celgene
Cortex
Cubist
Discovery Labs
Exelixis
Genzyme
Gilead
Idenix
Imclone
Kos Pharma
MGI Pharma
Protein Design Labs
Pain Therapeutics
Senomyx
Teva
Vertex
I'm still getting up to speed on some of these, like Exelixis and Idenix. I'm re-evaluating my previous pick of Medicis. PTIE is also "on the bubble", but I figure is probably still worth a modest position.
It takes a while to get a feel for so many companies, but on days like today when there's a broad market advance, having a well diversified portfolio sure seems like a great idea. If Cortex should have one of its temporary pre-data drops under $2, I'll be backing up the truck. Cubist is one I really like also - their antibiotic Cubicin is ramping up sales faster than any IV antibiotic in US history (it works against resistant staph aureus), and it should get expanded approval for bacteremia and endocarditis next year (it's already in use for these indications off label).
Now if I could only work up the nerve to nibble on GTCB :o) I still have grave doubts about more delays, but you never know. I'm going to have to check out some of Dew's other picks. Dendreon I looked at years ago, but decided to stay away from cancer vaccine companies, along with the gene therapy and stem cell areas.
